Evidence map›Paper›PMID 27126628›Full record

ArticleImmunology and cell biology2016

B-cell signaling in persistent polyclonal B lymphocytosis (PPBL).

Nadine Voelxen, Claudia Wehr, Sylvia Gutenberger, Baerbel Keller, Miriam Erlacher, Cecilia Dominguez-Conde, Daniela Bertele, Florian Emmerich, Milena Pantic, Stefanie Jennings and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunology and cell biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Polyclonal B-cell lymphocytosis in English bulldogs.Journal of veterinary internal medicine · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Nadine VoelxenCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Claudia WehrCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Sylvia GutenbergerCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Baerbel KellerCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Miriam ErlacherDivision of Pediatric Hematology and Oncology, University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Cecilia Dominguez-CondeCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Daniela BerteleDivision of Pediatric Hematology and Oncology, University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Florian EmmerichInstitute for Cell and Gene Therapy, University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Milena PanticDepartment of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Stefanie JenningsCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Mirzokhid RakhmanovCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Christian FoersterCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Uwe M MartensDepartment of Hematology and Oncology, SLK-Klinikum am Gesundbrunnen, Heilbronn, Germany.
Uwe PlatzbeckerUniversity Medical Center and Polyclinic I, Dresden, Germany.
Hans-Hartmut PeterCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Paul FischInstitute of Pathology, University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Kaan BoztugCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Hermann EibelCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Ulrich SalzerCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
Klaus WarnatzCenter for Chronic Immunodeficiency (CCI), University Medical Center Freiburg and University of Freiburg, Freiburg, Germany.
University of Freiburg · DEUniversity Medical Center Freiburg · DECeMM Research Center for Molecular Medicine · ATPolyclinic Medical Center · USSLK-Kliniken Heilbronn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persistent polyclonal B lymphocytosis (PPBL) is a benign hematological disorder characterized by a selective expansion of circulating polyclonal marginal zone (MZ)-like B cells. Previous reports demonstrated that cases of PPBL showed poor activation, proliferation and survival of B cells in vitro, yet the underlying defect remains unknown. Here we report for the first time an attenuated activation of the canonical NF-κB (nuclear factor of kappa light polypeptide gene enhancer in B cells) and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway after CD40 stimulation. This defect was selective, as alternative NF-κB signaling after CD40 stimulation and both B-cell receptor- and Toll-like receptor 9-mediated activation remained unaffected. Reduced canonical NF-κB activation resulted in decreased IκBα and CD40 expression in resting cells. In PPBL patients, expression of Bcl-xL in MZ-like B cells did not increase upon activation, consistent with the high apoptosis rates of PPBL-derived B cells that were observed in vitro. The B-cell phenotype of mice with selective knockouts of early components of the CD40 signaling pathway resembles PPBL, but sequencing corresponding genes in sorted MZ-like B cells of PPBL patients did not reveal relevant genetic alterations. Nevertheless, the frequently observed mutations in early signaling components of the NF-κB pathway in MZ lymphomas underline the relevance of our findings for the pathogenesis of PPBL.

Indexed as

AdultB-LymphocytesCD40 AntigensChild, PreschoolExtracellular Signal-Regulated MAP KinasesGene Expression RegulationHumansLymphocyte ActivationLymphocytosisMaleMiddle AgedPhenotypePhosphorylationReceptors, Antigen, B-CellRNA, MessengerSignal TransductionCD40 AntigensExtracellular Signal-Regulated MAP KinasesReceptors, Antigen, B-CellRNA, Messenger

Identifiers

PMID27126628
OpenAlexW2344466297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.